- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05305404
La dexaméthasone pour cibler le stress et les mécanismes du système immunitaire sous-jacents au besoin d'alcool
La dexaméthasone pour cibler le stress et les changements du système immunitaire pendant l'abstinence précoce chez les personnes atteintes d'un trouble lié à la consommation d'alcool (AUD)
This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Première phase 1
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Stony Brook, New York, États-Unis, 11794
- The Health Sciences Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Non-treatment seeking heavy drinking men and women with AUD
- Age range 18-55,
- Body Mass Index (BMI) of 18-35
- Positive ethylglucuronide (EtG) urine toxicology screen for alcohol
- Able to provide informed written and verbal consent
- Able to read English and complete study evaluations
- Good health as verified by screening examination.
Exclusion Criteria:
- Meet criteria for Substance Use Disorder (SUD) or other psychoactive substances, excluding nicotine
- Unable to remain abstinent for five days
- Need for a medically assisted detoxification
- Regular use of steroids, anticonvulsants, sedatives/hypnotics, prescription analgesics, other anti-hypertensives, anti-arrythmics, antiretroviral medications, tricyclic antidepressants, naltrexone, disulfiram, and any other psychoactive medications with the exception of stabilization on Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Psychotic or severely psychiatrically disabled
- Significant underlying medical conditions which would be of potential harm
- Pregnancy or breast feeding women;
- Women using monophasic contraceptives
- Electrocardiogram (EKG) evidence of clinically significant conduction abnormalities, (Bazlett's corrected QT (QTc) interval of >450 msec for men and QTc>470 msec for women).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Guanfacine
single dose of dexamethasone (1.5mg) administered orally |
1.5mg oral dexamethasone to be administered once at 11:00PM
Autres noms:
|
|
Comparateur placebo: Placebo
single dose of placebo administered orally |
oral placebo to be administered once at 11:00PM |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +5 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +5 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +15 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +15 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +30 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +30 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +5 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +5 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +15 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +15 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Délai: Change from baseline to +30 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +30 minutes following stress exposure
|
|
Hypothalamic-Pituitary-Adrenal (HPA)-axis response to stress exposure as assessed by cortisol
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by cortisol
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by cortisol
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by Adrenocorticotropic Hormone (ACTH)
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by ACTH
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by ACTH
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Interleukin (IL)-10 will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL-10 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL-10 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Interleukin 1 receptor antagonist (IL1-ra) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL1-ra will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL1-ra will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Tumor Necrosis Factor alpha (TNFa) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma TNFa will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma TNFa will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Tumor Necrosis Factor Receptor 1 (TNFR1) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma TNFR1 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Délai: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma TNFR1 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Anxiety as assessed using subjective report following stress exposure
Délai: Change from baseline to +5 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +5 minutes following stress exposure
|
|
Anxiety as assessed using subjective report following stress exposure
Délai: Change from baseline to +15 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +15 minutes following stress exposure
|
|
Anxiety as assessed using subjective report following stress exposure
Délai: Change from baseline to +30 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +30 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Délai: Change from baseline to +5 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +5 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Délai: Change from baseline to +15 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +15 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Délai: Change from baseline to +30 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +30 minutes following stress exposure
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Helen C Fox, PhD, Indiana University School of Medicine, Dept. of Psychiatry
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Les troubles mentaux
- Troubles liés à une substance
- Troubles induits chimiquement
- Troubles liés à l'alcool
- Alcoolisme
- Composés de soufre
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Composés polycycliques
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Stéroïdes, fluorés
- Dérivés de benzène
- Acides sulfoniques
- Acides de soufre
- Grossissement
- Benzènesulfonates
- Arylsulfonates
- Acides arylsulfoniques
- Dexaméthasone
- Dobésilate de calcium
Autres numéros d'identification d'étude
- R21AA029735 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .